CSIMarket
 
Inotiv Inc   (NOTV)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $7.9900 $0.54 7.248%
Day's High: $8.24 Week Perf: 24.45 %
Day's Low: $ 7.25 30 Day Perf: 141.39 %
Volume (M): 587 52 Wk High: $ 8.24
Volume (M$): $ 4,689 52 Wk Avg: $4.32
Open: $7.65 52 Wk Low: $1.61



 Market Capitalization (Millions $) 206
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) 585
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 33

Inotiv Inc
Inotiv Inc. is a leading provider of contract research services to the pharmaceutical, biotechnology, and medical device industries. The company was founded in 1992 and is headquartered in West Lafayette, Indiana, USA. Inotiv has a long history of providing high-quality analytical and bioanalytical services, as well as other technical services such as pharmacokinetic and toxicology studies.

Inotiv's services include bioanalysis, preclinical and clinical pharmacology, and clinical trial management. Their bioanalysis services help clients determine the concentration of drug molecules in blood, plasma, or other fluids. The preclinical and clinical pharmacology services include dose ranging studies, pharmacokinetics and pharmacodynamics studies, as well as toxicology studies, where they use animal models to evaluate the safety of drugs. Inotiv's clinical trial management services involve the coordination and management of clinical trials, including the selection of investigators, the design and implementation of protocols, and the management of data.

Inotiv is an accredited laboratory with over 20 years of experience in the industry, and their team of scientists and technicians possess the expertise and the knowledge to provide clients with the highest quality services. They have state-of-the-art facilities and equipment, which allows them to offer a broad range of analytical and bioanalytical services that meet or exceed regulatory requirements.

Inotiv's clients include pharmaceutical and biotechnology companies, as well as academic and government institutions. They have a significant presence in North America, Europe, and Asia, and their services have been relied upon to support the development of hundreds of drugs and medical devices.

In terms of financial performance, Inotiv has consistently grown revenues year over year, and has been profitable for over a decade. As of 2021, the company has a market capitalization of more than $350 million, making it a relatively small player in the contract research industry.

Overall, Inotiv's commitment to excellence in science, rigorous quality assurance, and a focus on customer satisfaction has made it a highly trusted partner to many of the world's leading pharmaceutical and biotechnology companies.


   Company Address: 2701 KENT AVENUE WEST LAFAYETTE 47906 IN
   Company Phone Number: 463-4527   Stock Exchange / Ticker: NASDAQ NOTV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Inotiv Inc

Inotiv Inc takes strategic steps to enhance profitability despite challenging financial period

Despite the challenges faced in recent financial periods, Inotiv Inc, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, is making strategic moves to improve its operations. Recently, the company announced its plan to insource its North American transportation operations in partnership with Vanguard Supply Chain Solutions LLC.
This decision comes at a time when Inotiv Inc has experienced a cumulative net loss of $-338 million in the 12-month period ending in the third quarter of 2023, resulting in a negative return on investment of -45.1%. In an effort to regain control and potentially reduce costs, the company aims to bring its transportation operations in-house. By doing so, Inotiv Inc hopes to streamline its logistics processes and enhance efficiency, ensuring smoother transportation of essential research materials, samples, and products throughout North America.

Inotiv Inc

A humbling three months by the company in the fourth quarter of 2023 earnings season

Inotiv, Inc. recently announced its plan to insource its North American transportation operations, which has raised concerns about the company's financial situation and its ability to generate positive returns. This decision comes after the company reported a significant net loss of $338 million during the 12-month period ending in the third quarter of 2023, leading to a negative return on investment of -45.1%.
By partnering with Vanguard Supply Chain Solutions LLC, Inotiv aims to bring its transportation operations in-house to gain better control and potentially save costs. However, it remains to be seen whether this move will yield the desired results, as the company has been struggling with declining financial performance in recent years.
In the financial span ending September 30, 2023, Inotiv reported a loss of $0.38 per share, compared to a loss of $9.59 per share in the previous year. Additionally, the company's EPS fell from $0.07 per share in the prior reporting season. This decline in earnings per share is a concerning trend and raises doubts about Inotiv's ability to generate profitability in the future.

Management Announcement

Inotiv, Inc. Partners with Vanguard to Insourcing Transportation Operations Amidst Cumulative Net Losses: Assessing Strategies for Growth

Published Wed, Dec 6 2023 9:30 PM UTC

Inotiv, Inc. Announces Plan to Insourcing North American Transportation Operations Despite Cumulative Net Losses
Inotiv, Inc., a prominent contract research organization specializing in nonclinical and analytical drug discovery and development services, as well as research models and related products and services, has recently revealed its intention to partner with Vang...

Inotiv Inc

Inotiv Inc's Robust Earnings Bolstered by $2.38 Million in Income Tax Provisions


As a financial analyst deeply involved in studying the most recent fiscal period of Inotiv Inc (NOTV), I am pleased to report that despite a decline in revenue, there are several positive indicators that point towards their ability to navigate the changing market landscape. Inotiv Inc, a leading player in the Medical Laboratories industry, has successfully turned a corner by converting a $0.15 deficit to earnings per share (EPS) of $0.07 per share in the third quarter of 2023.
While revenue fell by 8.802% to $157.47 million from $172.67 million in comparison to the same quarter the previous year, it is important to focus on NOTV's ability to adapt and generate income amidst challenging circumstances. This achievement is especially noteworthy as it reflects a significant improvement from the preceding quarter, which saw revenue at $151.46 million and a bottom-line figure of $-0.39 per share.

Inotiv Inc

Inotiv Inc's Second Quarter of 2023 Reveals a Solid Top-line Surge, But Looming Losses Raise Investor Concerns

As an AI language model, my analysis is purely based on the data and information given. After evaluating the financial reports presented, it is apparent that Inotiv Inc has undergone a considerable setback in its financial performance for the span closing March 31, 2023. The firm's revenues have shown a slight improvement of 7.947%, standing at $151.46 million, compared to the same period the previous year, where the figures stood at $140.31 million. This increase represents a marginal boost that is not sufficient to cover the escalated losses incurred.
Moreover, despite improved EPS figures of $-3.41 per share at the end of the previous reporting season compared to -$3.39 in the latest period, it is essential to note that losses have widened considerably from $-0.24 to $-0.39 per share this time around. This increase in losses is a significant red flag for potential investors, and it raises concerns over the firm's ability to maintain its sustainability long-term.






 

Inotiv Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com